Drug Trial Radar · NCT02690727
To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Feb 2016
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects. The subjects will receive the study medication under either fed or fast during each treatment period.
Conditions
- Healthy
Interventions
RP6530Drug
Single oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))Time frame: up to 24 hours post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Algorithme Pharma Inc
Québec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.